TR1: Notification of Major Shareholding
14 October 2021 - 03:28AM
UK Regulatory
Arix Bioscience PLC (ARIX) TR1: Notification of Major
Shareholding 13-Oct-2021 / 17:28 GMT/BST Dissemination of a
Regulatory Announcement, transmitted by EQS Group. The issuer is
solely responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)
i
1a. Identity of the issuer or the underlying issuer of existing ARIX BIOSCIENCE PLC
shares to which voting rights are attached ii:
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Takeda Ventures, Inc.
9625 Towne Centre Drive
City and country of registered office (if applicable)
San Diego, CA 92121 USA
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi: October 11, 2021
6. Date on which issuer notified (DD/MM/YYYY): October 12, 2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights
% of voting rights through financial Total of both Total number of voting
attached to shares instruments in % (8.A + rights held in issuer (8.A
(total of 8. A) (total of 8.B 1 + 8.B 8.B) + 8.B) vii
2)
Resulting situation on the date
on which threshold was crossed 6,160,083 N/A 6,160,083 6,160,083
or reached
Position of previous
notification (if 5.4% N/A 5.4%
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of Number of voting rights ix % of voting rights
shares
Direct Indirect Direct Indirect
ISIN code (if possible)
(DTR5.1) (DTR5.2.1) (DTR5.1) (DTR5.2.1)
Ordinary Shares
6,160,083 4.8%
GB00BD045074
SUBTOTAL 8. A 6,160,083
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Exercise/ Number of voting rights that may be acquired if
Type of financial Expiration Conversion Period the instrument is % of voting
instrument date x xi rights
exercised/converted.
N/A
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Physical or
Type of financial Expiration Exercise/ cash % of voting
instrument date x Conversion Number of voting rights rights
Period xi Settlement
xii
N/A
SUBTOTAL
8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and
does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying)
issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal X
entity (please add additional rows as necessary) xiv
% of voting rights if it % of voting rights through financial Total of both if it equals or
Name xv equals or is higher than the instruments if it equals or is higher than is higher than the notifiable
notifiable threshold the notifiable threshold threshold
Takeda
Pharmaceutical 100% ? 100%
Company Limited
Takeda
Pharmaceuticals 27.3% ? 27.3%
International AG
Takeda
Pharmaceuticals 100% ? 100%
U.S.A. Inc.
Takeda Ventures, 100% ? 100%
Inc.
10. In case of proxy voting, please identify:
Name of the proxy holder none
The number and % of voting rights held
The date until which the voting rights will be
held
11. Additional information xvi
9625 Towne Centre Drive
Place of completion
San Diego, CA 92121 USA
Date of completion October 12, 2021
Notes
i Please note this form should be read jointly with the
applicable Disclosure Guidance and Transparency Rules Chapter 5
(DTR5) available on the following link:
https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter
ii Full name of the legal entity and further specification of
the issuer or underlying issuer, provided it is reliable and
accurate (e.g. address, LEI, domestic number identity). Indicate in
the relevant section whether the issuer is a non UK issuer.
iii Other reason for the notification could be voluntary
notifications, changes of attribution of the nature of the holding
(e.g. expiring of financial instruments) or acting in concert.
iv This should be the full name of (a) the shareholder; (b) the
natural person or legal entity acquiring, disposing of or
exercising voting rights in the cases provided for in DTR5.2.1 (b)
to (h); (c) all parties to the agreement referred to in DTR5.2.1
(a) or (d) the holder of financial instruments referred to in
DTR5.3.1.
As the disclosure of cases of acting in concert may vary due to
the specific circumstances (e.g. same or different total positions
of the parties, entering or exiting of acting in concert by a
single party) the standard form does not provide for a specific
method how to notify cases of acting in concert.
In relation to the transactions referred to in DTR5.2.1 (b) to
(h), the following list is provided as indication of the persons
who should be mentioned:
- in the circumstances foreseen in DTR5.2.1 (b), the natural
person or legal entity that acquires the voting rights and is
entitled to exercise them under the agreement and the natural
person or legal entity who is transferring temporarily for
consideration the voting rights;
- in the circumstances foreseen in DTR5.2.1 (c), the natural
person or legal entity holding the collateral, provided the person
or entity controls the voting rights and declares its intention of
exercising them, and natural person or legal entity lodging the
collateral under these conditions;
- in the circumstances foreseen in DTR5.2.1 (d), the natural
person or legal entity who has a life interest in shares if that
person or entity is entitled to exercise the voting rights attached
to the shares and the natural person or legal entity who is
disposing of the voting rights when the life interest is
created;
- in the circumstances foreseen in DTR5.2.1 (e), the controlling
natural person or legal entity and, provided it has a notification
duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to
(d) or under a combination of any of those situations, the
controlled undertaking;
- in the circumstances foreseen in DTR5.2.1 (f), the deposit
taker of the shares, if he can exercise the voting rights attached
to the shares deposited with him at his discretion, and the
depositor of the shares allowing the deposit taker to exercise the
voting rights at his discretion;
- in the circumstances foreseen in DTR5.2.1 (g), the natural
person or legal entity that controls the voting rights;
- in the circumstances foreseen in DTR5.2.1 (h), the proxy
holder, if he can exercise the voting rights at his discretion, and
the shareholder who has given his proxy to the proxy holder
allowing the latter to exercise the voting rights at his discretion
(e.g. management companies).
v Applicable in the cases provided for in DTR5.2.1 (b) to (h).
This should be the full name of the shareholder who is the
counterparty to the natural person or legal entity referred to
DTR5.2 unless the percentage of voting rights held by the
shareholder is lower than the lowest notifiable threshold for the
disclosure of voting rights holdings in accordance with national
practices (e.g. identification of funds managed by management
companies).
(MORE TO FOLLOW) Dow Jones Newswires
October 13, 2021 12:28 ET (16:28 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Mar 2023 to Mar 2024